Project Grant HT94252510009
Award Date
3/1/25
Completion Date
2/28/29
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
Yale University was awarded an $11,577,868 project grant from the Defense Health Agency to research polycystic kidney disease under the Military Medical Research and Development program (CFDA 12.420). The grant period runs from September 1, 2021 through August 31, 2025. Through this funding, Yale researchers will investigate polycystic kidney disease as a disorder of glomerulotubular synchronization. The Military Medical Research and Development program aims to transform military and public...
This $309,528 Project Grant was awarded by the Defense Health Agency on February 1, 2024 under the Military Medical Research and Development program (CFDA 12.420) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI). The grant supports a project titled "Evaluating the Role of Somatic Mutations in Autosomal Dominant Polycystic Kidney Disease Using Single-Cell Genomics", which aims to advance scientific understanding and treatment of this condition through...
The Department of the Army Medical Command awarded a $3,674,785 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Johns Hopkins University for the "GENE THERAPY APPLICATION FOR POLYCYSTIC KIDNEY DISEASE" project. The award began on June 1, 2025 and is set to conclude on May 31, 2029. As a leading research institution, Johns Hopkins will leverage its expertise in biomedical research, clinical trials, and technological innovation to advance...
The Department of the Army Medical Command awarded Yale University a $2,639,485 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from December 2021 through November 2025 to investigate inhibition of the IRE1alpha-XBP1 pathway using toyocamycin as a novel approach to inhibit progression of autosomal dominant polycystic kidney and liver disease. The Military Medical Research and Development program supports basic, applied, and...
Yale University received a $1,731,409 project grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from June 2023 through May 2027 to investigate the role of immune cell-podocyte crosstalk in the pathogenesis of APOL1-FSGS and proteinuric kidney disease. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
Yale University received a $1,618,571 project grant award from the Defense Health Agency through the Military Medical Research and Development federal grant program (CFDA 12.420). The award will fund research from June 2023 through May 2027 to investigate the role of immune cell-podocyte crosstalk in the pathogenesis of APOL1-FSGS and proteinuric kidney disease. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
This four-year Project Grant from the Defense Health Agency provides $2,207,793 to investigate ido1 and dysregulated tryptophan metabolism in polycystic kidney disease. The grant supports research from April 1, 2023 through March 31, 2027. The Regents of the University of Colorado, doing business as the University of Colorado Denver, will investigate medical solutions for polycystic kidney disease under the Military Medical Research and Development program. This Defense Health Agency program...
This $761,506 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports advanced biomedical research at the University of New Mexico Health Sciences Center (UNM HSC) to identify therapeutically targetable molecules and pathways for the treatment of cystic kidneys in Tuberous Sclerosis Complex. The research aims to transform healthcare for military service members and the broader public by investigating innovative...
This $309,928 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate ferritin as a biomarker for progression of autosomal polycystic kidney disease. The 2-year project, which began on February 1, 2024, aims to advance scientific knowledge and develop innovative therapies in this area of kidney disease. KUMCRI, a...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $1,640,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "Therapeutic Parameters and Mechanism of Action of Anti-miR-17 Drugs in ADPKD," will fund research focused on developing novel therapeutic approaches for treating autosomal dominant polycystic kidney disease (ADPKD). The project aims to...